RECOMMENDATION: One and a half (1 ½) teaspoons mixed with water or juice each day or as otherwise directed by a healthcare professional.
DOES NOT CONTAIN: Gluten, yeast, soy, dairy, fish, shellfish, peanuts, tree nuts, egg, GMO’s, artificial colors, artificial sweeteners, or artificial preservatives.
Inositol is a compound often referred to as vitamin B8. Inositol aids in the metabolism of fats, and assists in the production of healthy cells in the bone marrow, intestines and ocular membranes. It also assists in the transportation of fats throughout the body and in neural communication. Inositol functions to support vascular health, and is important in hair growth. It is present in all body tissues, but the highest concentrations are found in the brain, heart and lens of the eye.
The term “inositol” typically refers to a specific isomer, “Myo-inositol” (MI). It is the most prominent form and occurs widely in nature. MI not only serves as a precursor molecule for inositol lipid synthesis, but also serves as a physiologically important osmolyte.(1)
Two inositol isomers have insulin-sensitizing capabilities: MI and D-chiro-inositol (DCI). These isomers are involved in many cellular functions, therefore abnormalities in their metabolism have been shown to be involved in the development of various health challenges, with a particular association with insulin resistance and associated health complications.(2)
While MI acts as a precursor to a number of signaling molecules which direct cellular activity, DCI is known to be an important secondary messenger in insulin signal transduction. Both MI and DCI have been demonstrated to improve androgen levels, increase the action of insulin, and to be supportive of healthy systolic blood pressure.(3)
Specifically, DCI functions to accelerate the dephosphorylation of glycogen and pyruvate dehydrogenase, rate limiting enzymes of non-oxidative and oxidative glucose disposal.(4)
Interestingly, a decrease in the urine excretion rate of DCI was shown to be linearly related to decreased insulin sensitivity.(4,5)
The combination of MI and DCI in the plasma at a physiological ratio of 40:1 is believed to be most advantageous clinically.(6) In both animal and human models, an associated depletion of inositol and an accumulation of intracellular sorbitol is commonly observed in the primary sites for the development of diabetic microvascular complications such as kidney, sciatic nerve, retinal and lens tissues.(7,8)
Also, an excessive amount of MI and a decreased amount of DCI is excreted in the urine of T2 diabetic human subjects, as well as experimental models,(9,10) resulting in a decrease DCI to MI urinary ratio. This abnormal pattern is seen in insulin sensitive tissue (liver, kidney, fat, muscle) in human and animal diabetic subjects.(10,11)
In comparing the glucose disposal rate (GDR) and non-oxidative GDR, it has been noted that both levels were significantly lower in T2 diabetes mellitus (DM) subjects compared to non-DM subjects, and that a reduction of non-oxidative glucose disposal may contribute to decreased whole-body glucose utilization.(12)
Interestingly, it has been demonstrated that the urinary clearance of DCI was increased almost six fold in PCOS women compared with normal women, but not MI clearance. Again, the urinary clearance of DCI correlated inversely with insulin sensitivity,(4) and administration of DCI accelerated glucose disposal and sensitized insulin action.
The 2013 International Consensus Conference on MI and DCI in Obstetrics and Gynecology examined seminal experimental papers and randomized clinical trials reporting the role and use of inositol(s) in clinical practice.(13)
Based on the existence of tissue-specific ratios, they recommended supplementing inositol in a 40 (MI) to 1 (DCI) ratio, as it has been demonstrated that inositol(s) supplementation could fruitfully affect different pathophysiological aspects pertaining Obstetrics and Gynecology.
While most commercially available inositol in the US is produced from corn, the inositol isomers utilized in Hormone Balancer™ are derived from rice, a gluten free source.
Hormone Balancer™ ™ is a pleasant tasting (semi-sweet) powder that disperses readily in water. Each serving supplies 5 grams of inositol as Myo-inositol and D-chiro-inositol in a 40:1 ratio. Each 8 ounce container of Hormone Balancer™ provides 45 servings.
Take One and a half (1½) teaspoons mixed with water or juice each day or as otherwise directed by a healthcare professional.
Does Not Contain
Gluten, yeast, soy, dairy, fish, shellfish, peanuts, tree nuts, egg, GMO’s, artificial colors, artificial sweeteners, or artificial preservatives.
Manufactured in a GMP registered facility in the USA.
- J Larner. D-Chiro-Inositol – Its Functional Role in Insulin Action and its Deficit in Insulin Resistance. Int J Exp Diabetes Res. 2002;3(1):47-660.
- Suzuki S, et al. Urinary chiro-inositol excretion is an index marker of insulin sensitivity in Japanese type ll diabetes. Diabetes Care. 1994 17:1465-1468.
- Dinicola S, et al. The Rationale of the Myo-Inositol and D-Chiro-Inositol Combined Treatment for Polycystic Ovary Syndrome. J Clin Pharmacology. 2014 Oct. 1-14.
- Al Winegrad. Banting lecture 1986. Does a common mechanism induce the diverse complication of diabetes? Diabetes 1987 36(3):396-406.
- H-HG Chang. Mechanisms underlying the abnormal inositol metabolisms in diabetes mellitus. University of Auckland. 2011 216 pages. https://researchspace.auckland.ac.nz./handle/2292/7154 [Consulte le janvier 30, 2013]
- Kennington AS, et al. Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus. N Engl J Med. 1990 Aug 9 323(6):373-8.
- Sun T, et al. Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Biophys Res Commun. 2002 May 10 293(3):1092-8.
- Asplin I, et al. Chiro-inositol deficiency and insulin resistance: a comparison the
chiro-inositol-and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type ll diabetic subjects. Proc Natl Acad Sci USA. 1993 Jul 1 90(13):5924-5928.
- Yoloyama H, et al. Non-oxidative glucose disposal is reduce in type 2 diabetes, but can be restored by aerobic exercise. Diabetes Obes Metab. 2008 May 10(5):400-7.
- Azziz R, et al. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab. 2005 90:4650-8.
- Norio M, Proiette E. The combined therapy with myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci. 2012 May 16(5):575-81.
- Dona G, et al. Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome. Eur. J Endocrin. 2012 166:703-710.
- Results from the International Consensus Conference on Myo-Inositol and D-chiro-inositol in Obstetrics and Gynecology: the link between metabolic syndrome and PCOS. Eur J obstet Gynedol Reprod Biol. 2015 Dec;195:72-6.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.